Radioimmunotherapy in the treatment of malignant astrocytomas

References

• Wingo P. A., Tong T., Bolden S. Cancer statistics, 1995. CA-A Cancer J. Clinicians 1995; 45: 8–30
   PubMed Web of Science ®Google Scholar
• Davis L. W. Presidential address: Malignant glioma—a nemesis which requires clinical and basic investigation in radiation oncology. Int. J. Radiat. Oncol. Biol. Phys. 1989; 16: 1355–1365
   PubMed Web of Science ®Google Scholar
• Bleehen N. M. Studies on high grade cerebral gliomas. Int. J. Radiat. Oncol. Biol. Phys. 1990; 18: 811–813
   PubMed Web of Science ®Google Scholar
• Salcman M., Kaplan R. S. Intracranial tumors in adults. Comprehensive Textbook of Oncology, A. R. Moossa, S. C. Schimpff, M. C. Robson. Williams & Wilkins, Baltimore, MD 1991; Vol. 2: 1339–1352
   Google Scholar
• Walker A. E., Robins M., Weinfeld E. D. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 1985; 35: 219–226
   PubMed Web of Science ®Google Scholar
• Allalunis–Turner M. J., Barron G. M., Day R. F., Fulton D. S., Urtasun R. C. Radiosensitivity testing of human primary brain tumor specimens. Int. J. Radiat. Oncol. Biol. Phys. 1992; 23: 339–343
   PubMed Web of Science ®Google Scholar
• Sheline G. E. Radiotherapy for high grade gliomas. Int. J. Radiat. Oncol. Biol. Phys. 1990; 18: 793–803
   PubMed Web of Science ®Google Scholar
• Taghian A., Ramsay J., Allalunis-Turner J., Budach W., Gioioso D., Pardo F., Okunieff P., Bleehen N., Urtasun R., Suit H. Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 1993; 25: 243–249
   PubMed Web of Science ®Google Scholar
• Gutin P. H., Leibel S. A., Wara W. M., Choucair A., Levin V. A., Philips T. L., Silver P., Da Silva V., Edwards M. S. B., Davis R. L., Weaver K. A., Lamb S. Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. J. Neurosurg. 1987; 67: 864–873
   PubMed Web of Science ®Google Scholar
• Salcman M. Neurobiology of Brain Tumors, Vol. 4, Concepts in Neurosurgery. Williams & Wilkins, Baltimore, MD 1991
   Google Scholar
• Burger P. C., Vogel F. S., Green S. B., Strike T. A. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 1985; 56: 1106–1111
   PubMed Web of Science ®Google Scholar
• Nelson J. S., Tsukada Y., Schoenfeld D., Fulling K., Lamarche J., Peress N. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 1985; 52: 550–554
   Web of Science ®Google Scholar
• Kornblith P. K., Welch W. C., Bradley M. K. The future of therapy for glioblastoma. Surg. Neurol. 1993; 39: 538–543
   PubMed Web of Science ®Google Scholar
• Taghian A., Suit H., Pardo F., Gioioso D., Tomkinson K., DuBoid W., Gerweck L. In vitro intrinsic radiation sensitivity of glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 1992; 23: 55–62
   PubMed Web of Science ®Google Scholar
• Weingart J., Brem H. Current management of high-grade gliomas. Contemp. Oncol. February, 1993; 19–31
   Google Scholar
• Kramer S. The hazards of therapeutic irradiation of the central nervous system. Clin. Neurosurg. 1968; 15: 301–318
   PubMedGoogle Scholar
• Leibel S. A., Sheline G. E. Radiation therapy for neoplasms of the brain. J. Neurosurg. 1987; 66: 1–22
   PubMed Web of Science ®Google Scholar
• Brady L. W., Woo D. V., Markoe A., Dadparvar S., Karlsson U., Rackover M., Peyster R., Emrich J., Miyamoto C., Steplewski Z., Koprowski H. Treatment of malignant gliomas with 125I labeled monoclonal antibody against epidermal growth factor receptor. Antib. Immunoconj. Radiopharm. 1990; 3: 169–179
   Google Scholar
• Brady L. W., Markoe A. M., Woo D. V., Amendola B. E., Karlsson U., Rackover M. A., Koprowski H., Steplewski Z., Peyster R. G. Iodine-125 labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme. Front Rad. Ther. Oncol. 1990; 24: 151–160
   PubMedGoogle Scholar
• Brady L. W., Miyamoto C., Woo D. V., Rackover M., Emrich J., Bender H., Dadparvar S., Steplewski Z., Koprowski H., Black P., Lazzaro B., Nair S., McCormack T., Nieves J., Morabito M., Eshleman J. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int. J. Radiat. Oncol. Biol. Phys. 1991; 22: 225–230
   Web of Science ®Google Scholar
• Chatel M., Lebrun C., Frenay M. Chemotherapy and immunotherapy in adult malignant gliomas. Curr. Opin. Oncol. 1993; 5: 464–473
   PubMedGoogle Scholar
• Czuczman M. S., Straus D. J., Divgi C. R., Garin-Chesa P., Finn R., Graham M., Larson S., Old L. J., Scheinberg D. A. A phase I dose escalation trial of 131I-labeled monoclonal antibody OKB7 in patients with B cell lymphoma. Antibod. Immunoconj. Radiopharm. 1992; 5: 344
   Google Scholar
• Jaeckle K. A. Immunotherapy of malignant gliomas. Semin. Oncol. 1994; 21: 249–259
   PubMed Web of Science ®Google Scholar
• Scheinberg D. A., Schwartz M. A., Lovett D., Redner A., Finn R. D., Graham M. C., Divgi C. R., Old L. J., Larson S. Dose escalation trial of 131I-M195 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. Antibod. Immunoconj. Radiopharm. 1992; 5: 345
   Google Scholar
• Bleehan N. N., Ford J. M. Radiotherapy, hyperthermia, and photodynamic therapy for central nervous system tumors. Curr. Opin. Oncol. 1993; 5: 458–463
   PubMedGoogle Scholar
• Kaye A. H., Hill J. S. Photodynamic therapy of brain tumors. Ann. Acad. Med. Singapore 1993; 22: 470–481, Suppl. 3
   PubMedGoogle Scholar
• Origitano T. C., Reichman O. H. Photodynamic therapy for intracranial neoplasms: development of an image-based computer-assisted protocol for photodynamic therapy of intracranial neoplasms. Neurosurgery 1993; 32: 587–595
   PubMed Web of Science ®Google Scholar
• Kato K., Yoshida J., Mizuno M., Sugita K., Emi N. Retroviral transfer of herpes simplex thymidine kinase gene into glioma cells causes targeting of gancyclovir cytotoxic effect. Neurol. Med. Chir. 1994; 34: 339–344
   PubMedGoogle Scholar
• Kim J. H., Kim S. H., Brown S. L., Freytag S. O. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res. 1994; 54: 6053–6056
   PubMed Web of Science ®Google Scholar
• Olivi A., Brem H. Interstitial chemotherapy with sustained-release polymer systems for the treatment of malignant gliomas. Recent Results Cancer Res. 1994; 135: 149–154
   PubMedGoogle Scholar
• Gutin P. H., Shrieve D. C., Larson D. A., Sneed P. Interstitial brachytherapy and hyperthermia for malignant gliomas. J. Neuro-Oncol. 1993; 17: 161–166
   PubMed Web of Science ®Google Scholar
• Sneed P. K., Larson D. A., Gutin P. H. Brachytherapy and hyperthermia for malignant astrocytomas. Semin. Oncol. 1994; 21: 186–197
   PubMed Web of Science ®Google Scholar
• Chin H. W., Letkowitz D. M., Eisenberg R. L. Treatment options in high-grade brain tumors: brain brachytherapy. Radiographics 1992; 12: 721–729
   PubMed Web of Science ®Google Scholar
• Malkin M. G. Interstitial brachytherapy of malignant gliomas: the Memorial Sloan-Kettering Cancer Center experience. Recent Results Cancer Res. 1994; 135: 117–125
   PubMedGoogle Scholar
• Brada M., Laing R. Radiosurgery/stereotactic external beam radiotherapy for malignant brain tumors: the Royal Marsden Hospital experience. Recent Results Cancer Res. 1994; 135: 91–104
   PubMedGoogle Scholar
• Mehta M. P., Masciopinto J., Rozental J., Levin A., Chappell R., Bastin K., Miles J., Turski P., Kubsad S., Mackie T., Kinsella T. Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int. J. Radiat. Oncol. Biol. Phys. 1994; 30: 541–549
   PubMed Web of Science ®Google Scholar
• Libermann T. A., Nusbaum H. R., Razon N., Kris R., Lax I., Soreq H., Whittle N., Waterfield M. D., Ulrich A., Schlessinger J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985; 313: 144–147
   PubMed Web of Science ®Google Scholar
• Libermann T. A., Nusbaum H. R., Razon N., Kris R., Lax I., Soreq H., Whittle N., Waterfield M. D., Ulrich A., Schlessinger J. Mplification and overexpression of the EGF receptor gene in primary human glioblastomas. J. Cell Sci 1985a; 3: 161–172, Suppl.
   Google Scholar
• Bloom H. J. G. Intracranial tumors: response and resistance to therapeutic endeavors, 1970–1980. Int. J. Radiat. Oncol. Biol. Phys. 1982; 8: 1083–1113
   PubMed Web of Science ®Google Scholar
• Harris A. L. The epidermal growth factor receptor as a target for therapy. Cancer Cells 1990; 2: 321–323
   PubMed Web of Science ®Google Scholar
• Libermann T. A., Razon N., Bartal A. D., Yarden Y., Schlessinger J., Soreq H. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. 1984; 44: 753–760
   PubMed Web of Science ®Google Scholar
• Tannock I. E., Hill R. P. The Basic Science of Oncology. McGraw-Hill, New York 1992
   Google Scholar
• Carpenter G., Cohen S. 125I-labeled human epidermal growth factor: binding, internalization, and degradation in human fibroblasts. J. Cell. Biol. 1976; 71: 159–171
   PubMed Web of Science ®Google Scholar
• Carpenter G., Cohen S. Epidermal growth factor. J. Biol. Chem. 1990; 265: 7709–7712
   PubMed Web of Science ®Google Scholar
• Carpenter G., King L., Jr., Cohen S. Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature 1978; 276: 409–410
   PubMed Web of Science ®Google Scholar
• Chen W. S., Lazar C. S., Lund K. A., Welsh J. B., Chang C.-P., Walton G. M., Der C. J., Wiley H. S., Gill G. N., Rosenfeld M. G. Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation. Cell 1989; 59: 33–43
   PubMed Web of Science ®Google Scholar
• Murthy U., Basu A., Rodeck U., Herlyn M., Ross A. H., Das M. Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch. Biochem. Biophys. 1987; 252: 549–560
   PubMed Web of Science ®Google Scholar
• Takahashi H., Herlyn D., Atkinson B., Powe J., Rodeck U., Alavi A., Bruce D. A., Koprowski H. Radio-immunodetection of human glioma xenografts by monoclonal antibody to epidermal growth factor receptor. Cancer Res. 1987; 47: 3847–3850
   PubMed Web of Science ®Google Scholar
• Haigler H., Ash J. F., Singer S. J., Cohen S. Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. Proc. Natl. Acad. Sci. USA 1978; 75: 3317–3321
   PubMed Web of Science ®Google Scholar
• Stoscheck C. M., Carpenter G. Down regulation of epidermal growth factor receptors: direct demonstration of receptor degradation in human fibroblasts. J. Cell. Biol. 1984; 98: 1048–1053
   PubMed Web of Science ®Google Scholar
• Black K. L., Chio C.-C. Increased opening of blood-tumour barrier by leukotriene C4 is dependent on size of molecules. Neurol. Res. 1992; 14: 402–404
   PubMedGoogle Scholar
• Humphrey P. A., Wong A. J., Vogelstein B., Friedman H. S., Werner M. H., Bigner D. D., Bigner S. H. mplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res. 1988a; 48: 2231–2238
   PubMed Web of Science ®Google Scholar
• Humphrey P. A., Wong A. J., Vogelstein B., Zalutsky M. R., Fuller G. N., Archer G. E., Friedman H. S., Kwatra M. M., Bigner S. H., Bigner D. D. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc. Natl. Acad. Sci. USA 1990; 87: 4207–4211
   PubMed Web of Science ®Google Scholar
• Bigner S. H., Burger P. C., Wong A. J., Werner MFL, Hamilton S. R., Muhlbaier L. H., Vogelstein B., Bigner D. D. Gene amplification in malignant gliomas: clinical and histopathologic aspects. J. Neuropathol. Exp. Neurol. 1988; 47: 191–205
   PubMed Web of Science ®Google Scholar
• Wheldon T. E. Targeting radiation to tumours. Int. J. Radiat. Biol. 1994; 65: 109–116
   PubMed Web of Science ®Google Scholar
• Adelstein S. J., Kassis A. I. Radiobiologic implications of the microscopic distribution of energy from radionuclides. Nucl. Med. Biol. 1987; 14: 165–169, Int. J. Radiat. Appl. Instrum. Part B
   Web of Science ®Google Scholar
• Woo D. V., Markoe A. M., Brady L. W., Koprowski C., Koprowski H., Heindel N. D., Mattis J. Monoclonal antibodies for use in radiotherapy and diagnosis. Am. J. Clin. Oncol. (CCT) 1988; 11: 355–361
   PubMed Web of Science ®Google Scholar
• Woo D. V., Li D., Brady L. W., Emrich J., Mattis J., Steplewski Z. Uger electron damage induced by radioiodinated iodine-125 monoclonal antibodies. The Present and Future Role of Monoclonal Antibodies in the Management of Cancer: Front Radiat Ther Oncol, J. M. Vaeth, J. L. Meyer. S. Karger, Basel 1990a; Vol. 24: 47–63
   Google Scholar
• Dillman L. T. Radionuclide decay schemes and nuclear parameters for use in radiation dose estimation. J. Nucl. Med. 1969; 10: 7–13, Suppl. 2
   Web of Science ®Google Scholar
• Feige Y. The auger cascade and therapeutic application of 125I. Curr. Top. Radiat. Res. Quar. 1977; 12: 3–11
   Google Scholar
• Goodhead D. T. Spatial and temporal distribution of energy. Health Phys. 1988; 55: 231–240
   PubMed Web of Science ®Google Scholar
• Persson L. The auger electron effect in radiation dosimetry. Health Phys. 1994; 67: 471–476
   PubMed Web of Science ®Google Scholar
• Ertl H. H., Feinendegen L. E., Heiniger H. J. Iodine-125, a tracer in cell biology: physical properties and biological aspects. Phys. Med. Biol. 1970; 15: 447–456
   PubMed Web of Science ®Google Scholar
• Unak P., Unak T. Microscopic energy absorption of the DNA molecules from auger electrons of iodine-125. Appl. Radiat. Isot. 1988; 39: 1037–1040, Int. J. Radiat. Appl. Instrum. Part A
   Web of Science ®Google Scholar
• National Council on Radiation Protection and Measurements. A Handbook of Radioactivity Measurements Procedures. Bethesda, MD 1989; 431, NCRP Report No. 58
   Google Scholar
• Wrenn M. E., Howells G. P., Hairr L. M., Paschoa A. S. uger electron dosimetry. Health Phys. 1973a; 24: 645–653
   PubMed Web of Science ®Google Scholar
• Chan P. C., Lisco E., Lisco H., Adelstein S. J. The radiotoxicity of I-125 in mammalian cells, II: a comparative study on cell survival and cytogenetic responses to 125IUdR, 131IUdR, and 3HTdR. Radiat. Res. 1976; 67: 332–343
   PubMed Web of Science ®Google Scholar
• Hofer K. G., Keough G., Smith J. M. Biological toxicity of auger emitters: molecular fragmentation versus electron irradiation. Curr. Top. Radiat. Res. Quar. 1977; 12: 335–354
   Google Scholar
• Kassis A. I., Sastry K. S. R., Adelstein S. J. Kinetics of uptake, retention, and radiotoxicity of 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat. Res. 1987; 109: 78–89
   PubMed Web of Science ®Google Scholar
• Kassis A. I., Fayad F., Kinsey B. M., Sastry K. S. R., Taube R. A., Adelstein S. J. Radiotoxicity of 125I in mammalian cells. Radiat. Res. 1987; 111: 305–318
   PubMed Web of Science ®Google Scholar
• Hofer K. G., Hughes W. L. Radiotoxicity of intranuclear tritium, 125iodine and 131iodine. Radiat. Res. 1971; 47: 94–109
   PubMed Web of Science ®Google Scholar
• Bradley E. W., Chan P. C., Adelstein S. J. The radiotoxicity of iodine-125 in mammalian cells, I: effects on the survival curve of radioiodine incorporated into DNA. Radiat. Res. 1975; 64: 555–563
   PubMed Web of Science ®Google Scholar
• Martin R. F., Haseltine W. A. Range of radiochemical damage to DNA with decay of iodine-125. Science 1981; 213: 896–898
   PubMed Web of Science ®Google Scholar
• Linz U., Stocklin G. Chemical and biological consequences of the radioactive decay of iodine-125 in plasmid DNA. Radiat. Res. 1985; 101: 262–278
   PubMed Web of Science ®Google Scholar
• Commerford S. L., Bond V. P., Cronkite E. P. Radiotoxicity of intranuclear 125I atoms not bound to DNA. Int. J. Radiat. Biol. 1980; 37: 547–554
   Web of Science ®Google Scholar
• Epenetos A. A., Courtenay-Luck N., Pickering D., Hooker G., Durbin H., Lavender J. P., McKenzie C. G. ntibody guided irradiation of brain glioma by arterial fusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen. Br. Med. J. 1985a; 290: 1463–1466
   PubMed Web of Science ®Google Scholar
• Kalofonos H. P., Pawlikowska T. R., Hemingway A., Courtenay–Luck N., Dhokia B., Snook D., Sivolapenki G. B., Hooker G. R., McKenzie C. G., Lavender P. J., Thomas D. G. T., Epenetos A. A. ntibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J. Nucl. Med. 1989a; 30: 1636–1645
   PubMed Web of Science ®Google Scholar
• Larson S. M. Radiolabeled monoclonal anti-rumor antibodies in diagnosis and therapy. J. Nucl. Med. 1985; 26: 538–545
   PubMed Web of Science ®Google Scholar
• Riva P., Sturiale C., Arista A., Franceschi G., Spinelli A., Riva N., Casi M., Marian M. Intralesional radioimmunotherapy of glioblastomas: an effective treatment in recurrent tumours. Antibod. Immunoconj. Radiopharm. 1992; 5: 345
   Google Scholar
• Haseltine Williams J., Zhang Y., Shao Y., Bartholomew R., Mackinson D., Dillehay L. Response of human colorectal tumor cells to protracted irradiation: implications for radioimmunotherapy of colorectal cancer. Antibod. Immunoconj. Radiopharm. 1992; 5: 339
   Google Scholar
• Mendelsohn J. Monoclonal antibodies against the epidermal growth factor receptor: a model for anticancer therapy. Proc. Am. Assoc. Cancer Res. 1990; 31: 460–461
   Google Scholar
• D'Avella D., Cicciarello R., Albiero F., Mesiti M., Gagliardi M. E., Russi E., D'Aquino A., Tomasello F., d'Aquino S. Quantitative study of blood–brain barrier permeability changes after experimental whole-brain radiation. Neurosurgery 1992; 30: 30–34
   PubMed Web of Science ®Google Scholar
• Qin D. X., Zheng R., Tang J., Li J. X., Hu Y. H. Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1990; 19: 1507–1510
   PubMed Web of Science ®Google Scholar
• Trnovec T., Kallay Z., Bezek S. Effects of ionizing radiation on the blood brain barrier permeability to pharmacologically active substances. Int. J. Radiat. Oncol. Biol. Phys. 1990; 19: 1581–1587
   PubMed Web of Science ®Google Scholar
• Baba T., Black K. L., Ikezaki K., Chen K., Becker D. P. Intracarotid infusion of leukotriene C4 selectively increases blood–brain barrier permeability after focal ischemia in rats. J. Cereb. Blood Flow Metab. 1991; 11: 638–643
   PubMed Web of Science ®Google Scholar
• Black K. L., Hoff J. T., McGillicuddy J. E., Gebarski S. S. Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans. Ann. Neurol. 1986; 19: 592–595
   PubMed Web of Science ®Google Scholar
• Black K. L., King W. A., Irezaki K. Selective opening of the blood-tumor barrier by intracarotid infusion of leukotriene C4. J. Neurosurg. 1990; 72: 912–916
   PubMed Web of Science ®Google Scholar
• Inamura T., Black K. L. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J. Cereb. Blood Flow Metab. 1994; 14: 862–870
   PubMed Web of Science ®Google Scholar